Are you a clinician, investor, journalist, or patient advocate? We'd love to hear from you.
However you've found us, there's a reason to talk.
Trial collaboration, the protocol, and the underlying mechanism.
The investment opportunity, the roadmap, and multi-indication upside.
Story background, data, and interviews with the team.
What the science means for ALS and neurodegeneration today.